JPRN-UMIN000000965
Completed
未知
Phase 2 study of cisplatin and pemetrexed in previously treated patients with malignant pleural mesothelioma - Phase 2 study of cisplatin and pemetrexed in previously treated patients with malignant pleural mesothelioma
ConditionsMalignant pleural mesothelioma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignant pleural mesothelioma
- Sponsor
- Hyogo College of Medicine
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Serious or uncontrolled complication 2\. Active infection 3\. Active concomitant malignancy 4\. Symptomatic brain metastasis 5\. With prior unapproved drugs or investigational new drugs 6\. With a history of sensitivity to platinum agent, folic acid or vitamin B12 7\. Women with confirmed, lactating or suspected pregnancy. Patients who won't avoid pregnancy. 8\. Peripheral neuropathy \>\= grade 2 9\. Interstitial pneumonia or fibroid lung 10\. Medically endorsed anticonception can't be assured till 90 days after the final administration 11\. Inappropriate patients for entry on this trial in the judgment of the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer.Previously untreated stageIIIB/IV non-squamous non-small-cell lung cancerJPRN-UMIN000002686Kinki-chuo chest medical center35
Active, not recruiting
Not Applicable
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) - SoMe Studymalignant pleural mesothelioma (MPM)MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2007-005894-77-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Active, not recruiting
Not Applicable
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
Active, not recruiting
Phase 1
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
Active, not recruiting
Not Applicable
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125